Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants by Gantenbein, Monika Herbst et al.
J. Perinat. Med. 36 (2008) 448–452 • Copyright  by Walter de Gruyter • Berlin • New York. DOI 10.1515/JPM.2008.064
Article in press - uncorrected proof
Side effects of angiotensin converting enzyme inhibitor
(captopril) in newborns and young infants
Monika Herbst Gantenbein1,*, Urs Bauersfeld2,
Oskar Baenziger1, Bernhard Frey1, Thomas
Neuhaus3, Felix Sennhauser4 and Vera Bernet1
1 Department of Intensive Care and Neonatology,
University Children’s Hospital Zurich, Switzerland
2 Department of Cardiology, University Children’s
Hospital Zurich, Switzerland
3 Department of Nephrology, University Children’s
Hospital Zurich, Switzerland
4 Department of Pediatrics, University Children’s
Hospital Zurich, Switzerland
Abstract
Aim: To analyze the side effects of captopril, an angio-
tensin converting enzyme inhibitor (ACEI) in newborn and
young infants.
Methods: Retrospective analysis of side effects in 43
patients with congenital heart disease after cardiac sur-
gery treated with captopril for heart failure during a two-
year period.
Results: Median age of the patients was 26 days (range
6–310 days), median weight 3.5 kg (range 1.9–7.9 kg).
Initial median dose of captopril was 0.17 mg/kg/day
(range 0.05–0.55 mg/kg/day), slowly increased over
3–33 days to a maximal median dose of 1.86 mg/kg/day
(range 0.2–2.3 mg/kg/day). All patients were additionally
treated with diuretics. Side effects occurred in 17
patients (renal impairment or failure in 6, low blood pres-
sure in 8, and oxygen saturation deficit in 3) requiring
cessation or interruption in seven patients with renal
impairment/failure (ns4), hypotension (ns1) and aorto-
pulmonary shunting with low pulmonary perfusion (ns2).
The six children who developed renal impairment or fail-
ure did so following a median delay of nine days after
reaching the final dose and weighed on average 500 g
less than the other patients (Ps0.046). All side effects
were fully reversible.
Conclusion: Side effects due to captopril were not dose-
related in newborns and infants in this study. However,
renal side effects occurred more often in smaller infants.
Routine monitoring of infants on ACEI should include
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renal function tests, blood pressure and transcutaneous
oxygen saturation measurements.
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heart failure; hypotension; infant; newborn; renal failure.
Introduction
In addition to diuretics as standard pharmacotherapy of
infants with congenital heart disease, the use of angio-
tensin converting enzyme inhibitors (ACEIs) has become
a mainstay in the treatment of children with heart failure
over the past 20 years w1, 12x. Several studies showed
the beneficial effect on morbidity, mortality, and quality
of life w2, 3, 10, 14x. Captopril has been useful for the
treatment of congestive heart failure and hypertension
w2, 6, 8x.
ACEIs have several mechanisms of action. First, they
inhibit the formation of angiotensin II, second, they
decrease bradykinin degradation and, third, they inhibit
norepinephrine release from sympathetic nerve endings.
All these effects produce significant vascular relaxation,
reduction of after-load and improvement in cardiac out-
put w3x. Captopril has a bioavailability of 75% in adults;
most of the drug is eliminated through the kidneys as
captopril (50%) and its inactive metabolites (50%) w2x.
Peak serum concentrations can be measured at 1–2 h
after administration, and the average half-life is 3.3 h.
ACEIs are well tolerated. Occasional side effects include
oliguria, acute renal failure, hypotension w2, 11, 12x,
hyperkalemia, anemia, neurological complications, and
dry cough in older children w3, 8x.
In the human newborn, plasma renin activity, renal
renin gene and angiotensin II receptor expression are sig-
nificantly higher than later in life and they all decrease
over the first years of life. Therefore, neonates are more
sensitive to the administration of ACEI compared with
adults. Both the potency and duration of action of cap-
topril appear to be substantially greater in this age group.
Therefore, the initial dose of ACEI in newborns and, par-
ticularly in preterm infants, should be considerably lower
and the speed of the increase of this drug should be
slower than in older individuals w3, 8x.
The purpose of the study was to evaluate the side-
effects, in particular the renal side-effects of captopril in
newborns and young infants with congenital heart
disease.
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Table 1 Main diagnoses of the 43 patients.
Diagnosis All patients Renal impairment Hypotension Oxygen saturation
deficit
Transposition of the great arteries 12 1 2 0
Hypoplastic left heart 4 1 1 2
DORV (double outlet right ventricle) 4 0 1 1
VSD (ventricular septal defect) 3 0 1 0
AIST (aortic isthmus stenosis) 3 1 0 0
Aortic stenosis 3 0 2 0
Pulmonary atresia 3 0 1 0
AV-canal (atrio-ventricular canal) 3 1 0 0
Interrupted aortic arch, fallot tetralogy, 2 each Fallot tetralogy 0 0
truncus arteriosus communis, tricuspid interrupted
valve atresia aortic arch
Patients and methods
This study is a retrospective analysis of 43 newborns and young
infants treated with captopril. All patients were hospitalized in
the neonatal ward of the University Children’s Hospital Zurich
after surgical correction of congenital heart disease. The follow-
ing data were extracted from the patients’ files: gender, age,
weight and heart disorder, bypass time, as well as present med-
ication (e.g., diuretics), vital parameters and renal function. In all
these patients captopril was commenced after the surgical pro-
cedure, based on published beneficial responses to this medi-
cation w8, 10, 16x and based on hospital guidelines. Captopril
was generally started with a single oral test dose of 0.05
mg/kg, and, if well tolerated, regular treatment was started.
Dose adjustments were individualized according to the response
of each patient, and, if required, doses could be increased in a
stepwise manner as frequently as every eight to 24 h. Patients
who showed no significant drop in blood pressure 30–60 min
after captopril administration could immediately proceed to the
next higher dose. Blood pressure was measured indirectly
according to Riva-Rocci with an oscillometric method. In new-
borns (up to 28 days of life), significant drop in blood pressure
was defined as a decrease of mean blood pressure to a value
of less than mean blood pressure equal to actual ‘gestational’
age minus ten percent, measured twice in an interval of five
minutes in a quiet or sleeping child. In infants of up to three
months of age, our mean blood pressure limit is 45 mmHg.
Measurements were done twice as well and low blood pressure
was defined as ten percent below the limit. To prevent hypoten-
sion by administration of captopril together with diuretics, diu-
retics have to be administrated at least 60 min after captopril.
Renal impairment was defined as creatinine and urea nitrogen
levels above the upper limits for the different age groups accord-
ing to our hospital laboratory guidelines and renal failure was
defined when potassium levels were increased as well.
Oxygen desaturation was defined in all patients as transcu-
taneous oxygen saturation drop for more than five minutes
below 90% in children without a cyanotic cardiac disease. For
children with a cyanotic lesion, transcutaneous oxygen satura-
tion had to be over 75–80%, depending on the underlying
disease.
A dose reduction was recommended for patients with renal
impairment or failure and/or hypotension as well as for patients
with a cyanotic heart disease and drop of transcutaneous oxy-
gen saturation below 75–80% after medication for more than 5
min.
For detection and monitoring of the known and previously
reported side effects, the following data were collected: blood
pressure (before, 30 and 60 min after captopril administration),
blood tests for renal function every 3–6 days, including creati-
nine, potassium and urea nitrogen and fluid intake.
Differences between groups were analyzed using the Mann-
Whitney U-test. A P-value -0.05 was considered statistically
significant.
Results
The median age of the patients on starting captopril was
26 days (range 6–310 days) and the median weight
3.5 kg (range 1.9–7.9 kg). Twenty-three children were
newborns (5 of them born prematurely), 20 patients were
older than four weeks. The male-to-female ratio was
nearly 1:1. All patients were treated either after a correc-
tive or a palliative operation. Diagnoses of the patients
are summarized in Table 1. For close observation of any
possible side effects, all patients were hospitalized at the
time of captopril introduction.
Captopril was started with an initial dose of
0.05–0.55 mg/kg/day (median 0.17 mg/kg/day) in three
divided doses, thereafter and if tolerated, slow increase
in median increments of 0.34 mg/kg/day was started,
aiming for a target dose of 1.5 mg/kg/day (median final
dose 1.86 mg/kg/day, range 0.2–2.3 mg/kg/day). The
median duration to reach steady state dose was nine
days (range 3–33 days). All patients were additionally
treated with diuretics, on the day of captopril introduction
with furosemide at a median dose of 1.45 mg/kg/day
(range 0.37–12 mg/kg/day) and spironolactone (6.25 mg
once daily). Furosemide was replaced as quickly as
possible by hydrochlorothiazide on a median dose of
2.31 mg/kg/day (range 1.01–8.62 mg/kg/day) with con-
tinuing spironlactone therapy as part of heart failure ther-
apy if serum potassium levels were within the normal
range. In 26 children the treatment with captopril was
well tolerated and the therapy was clinically effective. In
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0) 17 patients we found the following side effects: renal
impairment/failure, hypotension, and arterial oxygen
saturation deficit (Table 2).
Renal impairment/failure
Renal impairment occurred in five and renal failure in one
patient (total 14%) with increase of median blood urea
nitrogen up to 11.25 mmol/L (range 8.7–16 mmol/L) and
creatinine up to 74 mmol/L (range 50–102 mmol/L) (Table
2). The patient with renal failure was born with hypoplas-
tic left heart syndrome and required Norwood I proce-
dure. He developed renal failure with high urea and
creatinine and maximal potassium of 6.2 mmol/L. In three
patients captopril had to be ceased permanently, includ-
ing the patient with renal failure. In one child the treat-
ment had to be interrupted and in another patient
captopril was temporarily lowered to a dose of 0.54
mg/kg/day until renal function normalized. Afterwards the
medication was re-increased without renal problems. The
sixth patient had raised urea nitrogen at full dose, which
normalized spontaneously within three days. In the other
five children urea nitrogen and creatinine crossed the
upper normal limits following a median delay of nine days
after reaching the final dose.
We looked at the bypass time in the different groups
as a factor for renal problems and could not show a sig-
nificant difference between the renal impairment/failure
group and the patients without side effects (Ps0.26).
The median age of these six children (18.5 days, range
11–118 days) was not significantly different than the
median age of the other children without renal problems
(Ps0.66), but their weight (3.1 kg, range 1.9–3.5 kg) was
significantly lower (Ps0.046). The maximal median cap-
topril dose of the infants who developed renal impairment
or failure was 1.24 mg/kg/day (0.17–2 mg/kg/day) com-
pared to 1.67 (0.24–2.3 mg/kg/day) in patients without
renal dysfunction (Ps0.18).
The furosemide dose at the beginning of captopril
treatment was 2.95 mg/kg/day (range 1.6–12 mg/kg/day)
and 3.28 mg/kg/day (range 1–11 mg/kg/day) in the renal
impairment/failure group- and non-renal group, respec-
tively (Ps0.67). Renal impairment/failure was reversible
in all patients.
Potassium levels have not been measured regularly for
all patients, therefore no statistical analysis was done.
Hypotension
Eight children (19%) repeatedly showed hypotensive epi-
sodes and treatment was adjusted either by dose reduc-
tion or by slower increase of the dose. Diagnoses are
listed in Table 1. The children with hypotensive episodes
had a median reduction of the systolic blood pressure of
23.8% after administration of captopril (compared to
13% in the group of patients without side effects). The
median reduction of the diastolic blood pressure was
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32.7% (vs. 17.4%) and 26% (57 to y2) for the mean
blood pressure. Compared to the patients without side
effects, the time on bypass was significantly longer
(Ps0.002).
The median age of these eight patients was 28 days
(range 6–65 days) and their median weight was 3.23 kg
(range 2.8–4.3 kg) (Table 2). The maximal captopril dose
was 1.83 mg/kg/day. These patients received the highest
furosemide dose (4.5 mg/kg/day) when captopril was
started. The patients with low blood pressure had a ten-
dency to a longer time period until reaching the maximal
dose and to require more dose adjustments compared
to the rest of the patients (16 days, 7 steps vs. 10 days,
6 steps, respectively).
Oxygen saturation deficit
Three infants had transcutaneous oxygen saturation
drops on captopril. All of them had single ventricle
pathology. In two patients treatment was interrupted and
in one of them treatment was even stopped because of
bad general state of health. One child normalized his
transcutaneous oxygen saturation when the daily dose
was reduced. The median age and weight of these three
patients were 17 days and 3.3 kg (Table 2). The median
maximal captopril dose was 1.23 mg/kg/day. The individ-
ual blood pressures in these three patients were 70/40
with a mean of 50, 74/40 with a mean of 47 and 56/28
with a mean of 38. Reduction of blood pressure is shown
in Table 2.
Discussion
In the present study we evaluated retrospectively the side
effects of captopril in newborn and young infants with
congenital heart disease. The most common side effect
was hypotension (ns8), which required adaptation of
drug dose. A possible explanation for the decreased
blood pressure may be the combination of captopril with
furosemide, although they were not given at the same
time.
The second most common side effect was reversible
renal impairment or failure. The weight of patients with
renal impairment/failure was significantly lower compared
to the weight of infants without renal side effects. We
could not find a correlation between renal side effects
and diuretic therapy. In fact, the infants with renal pro-
blems were on lower doses of diuretics compared to the
infants without renal side effects.
Leversha et al. w5x described an association between
young age, low weight, left-to-right shunt and renal fail-
ure in children on captopril. However, renal impairment
was not dose related. These authors found side effects
in 28% of 63 patients, who had been treated with a mean
maximal dose of ACEI of 0.3 mg/kg/day (range
0.04–0.94 mg/kg/day): hypotension occurred in nine
children and renal failure was observed in eight infants.
Renal failure developed within five days of starting treat-
ment and all of the renal failure patients were less than
four months of age, had left-to-right shunts and received
digoxin and diuretics. The authors recommended special
care to the small infants and especially suggested that
potassium sparing diuretics should be discontinued
when starting ACEI. Similarly, Shaddy et al. w11x pre-
sented a group of 10 infants, of whom the smallest and
youngest child developed acute renal dysfunction after a
single dose of 0.5 mg/kg captopril. Hypotension was
found in seven of the ten patients.
Focusing on operative bypass time as an important
factor for renal dysfunction we could not find a difference
between the renal dysfunction group and the patients
without any side effect. Compared to that, bypass time
was significantly longer in the patients with hypotension.
We could not find a physiological explanation for this
finding.
The three patients with oxygen saturation deficit had
been diagnosed with a single ventricle. The drop in arte-
rial oxygen saturation may be explained by decreasing
peripheral arterial resistance and consecutive mismatch
of the lung and body perfusion. Because the number of
patients in this group is very small this speculation needs
verification in a prospective study.
Even though our patients had an adequate dose of
captopril of -1.9 mg/kg/day, 39.5% of them showed
side effects. In our study renal side effects occurred with
an average delay of nine days after achieving full dose.
In some other studies side effects usually appeared
shortly after beginning treatment or when patients
reached the full dose w5, 10, 12x. However, there is also
evidence for a delayed and unpredictable onset of side
effects unrelated to the dose w4, 6x. Tack et al. w17x ret-
rospectively analyzed nine young infants after a starting
dose of 0.3 mg/kg captopril. The systolic blood pressure
decreased significantly in all infants. After halving the
dosage, hypotension still occurred between 1–54 days
after starting treatment. During therapy four infants had
an increase in urea and creatinine values in association
with oliguria. Therefore, they recommend a starting dose
of 0.1–0.2 mg/kg/day and a maintenance dose of
0.6 mg/kg/day in premature infants. It is important for the
neonatologist and pediatrician to be aware of the delayed
and unpredictable side effects.
Early clinical trials used high doses of captopril of up
to 3.5 mg/kg/day in infants and of up to 6 mg/kg/day in
older children which caused dose-related adverse effects
w4, 6, 10x. Calligaro and Burman w2x described a dose-
relationship with renal dysfunction in neonates on diuret-
ics and ACEI. In our study hypotension was related to
high doses of captopril, but renal side effects occurred
with even lower doses. Conservative initial doses are
recommended (0.05–0.1 mg/kg/day), especially in neo-
nates, who are highly susceptible to adverse effects
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associated with ACEIs w1, 9, 13, 14x. Starting with low
doses may decrease the incidence of adverse reactions
and may improve the patients’ tolerance of this treat-
ment. It is important to select patients carefully, identify
their risk factors (risk profile: congestive heart failure, high
doses of diuretics, elevated plasma renin activity, volume
depletion, single ventricle) and use more rational and
patient adapted dosing schemes. Shaw et al. w12x sur-
veyed 20 young infants on captopril with an initial dose
of 0.25–0.5 mg/kg/day and a maximal daily dose of
0.88–2.5 mg/kg (mean 1.3 mg/kg/day), all being treated
with furosemide (2.2–8.5 mg/kg/day) and spironolactone
(1.5–10 mg/kg/day). Side effects had been seen in four
patients – two with mild hypotension and two with renal
impairment, all of them recovered on a lower dose. The
authors concluded that patients benefited from a low
dose, at most 1.5 mg/kg/day. This has been supported
by Scammell et al. w10x in a similar study. O’Dea et al. w7x
used low initial doses (0.13 mg/kg/day) and increased to
a maximum of 0.85 mg/kg/day to treat neonatal hyper-
tension. They found a positive antihypertensive response
to captopril and this regimen was not associated with
hypotension, changes in serum creatinine or reduction in
urine output. They recommended captopril as an effec-
tive antihypertensive drug in neonates and suggested a
low initiating dose with the lowest maintenance dose
possible that still elicited an effective clinical response.
Beside the limitation that this is a retrospective study,
it is very difficult to attribute a side-effect of a drug,
directed to such a clinical setting. Side effects of drugs
are sometimes influenced by unobvious or not measur-
able factors in the cardio-vascular status of a patient, or
the result of individual pharmacokinetics of a patient on
different drugs.
A review of the current literature about captopril did
not allow us to draw a conclusive strategy for drug
administration and maximal dosage. From our experi-
ence, we suggest a dose range between 1 and 1.5
mg/kg/day in newborns and infants w1, 7, 12x. All pub-
lished studies showed that cardiac function was not
improved at higher doses, but the risk of serious side
effects was generally increased, especially renal dysfun-
cion and hypotension w1, 15, 17x. Therefore, a dose of
1.5 mg/kg/day should not be exceeded in this age-group
and careful monitoring is mandatory, especially in the
younger and smaller infants w5, 11x.
Conclusion
Renal side effects due to captopril were not dose related
in newborns and infants in our study. However, renal side
effects occurred more often in the smaller infants. Other
common side effects are hypotension and arterial oxygen
saturation deficit. Therefore, routine monitoring in infants
treated with captopril should include renal function tests,
blood pressure, and transcutaneous arterial oxygen
saturation measurements. Long-term studies in a larger
population are required to confirm our findings and to
elicit the benefits of captopril.
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